About Altimmune, Inc.
Clinical-stage biotech developing pemvidutide, a GLP-1/glucagon dual agonist for obesity and liver disease. No dividend, binary Phase 3 event risk dominates price action. Not a steady-income CSP name — gap risk around trial readouts can be extreme.
Biotechnology